Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells.

Urology - 1 Feb 2003

Fechner G, Perabo F G E, Schmidt D H, Haase L, Ludwig E, Schueller H, Blatter J, Mller S C, Albers P

Abstract excerpt

OBJECTIVES: Despite clinical use, the radiosensitizing effect of gemcitabine (2'2'-difluorodeoxycytidine) in human transitional cell carcinoma (TCC) has not been shown to date. We investigated gemcitabine as a radiosensitizer for human TCC cells. METHODS: Monolayer cultures of RT112 (G1, p53 wild...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Transitional Cell
Share to Deoxycytidine
Share to Dose-Response Relationship, Radiation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gemcitabine

Share to In Situ Nick-End Labeling

Share to Radiation-Sensitizing Agents

Share to Radiotherapy Dosage

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 12597983
DOI: 10.1016/s0090-4295(02)02156-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-12597983-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells.PMID 12597983Read ↗

Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine.Semantic proximity Read ↗

Radiation induces p53-dependent cell apoptosis in bladder cancer cells with wild-type- p53 but not in p53-mutated bladder cancer cells.Semantic proximity Read ↗

Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation.Semantic proximity Read ↗

Involvement of p53 in gemcitabine mediated cytotoxicity and radiosensitivity in breast cancer cell lines.Semantic proximity Read ↗

Cell Cycle Checkpoint Function in Bladder CancerSemantic proximity Read ↗

Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer.Semantic proximity Read ↗

Supraadditive effect of 2 ′ ,2 ′ -difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell linesSemantic proximity Read ↗

Influence of p53 status on radiation and 5-flourouracil synergy in pancreatic cancer cells.Semantic proximity Read ↗

End-joining deficiency and radiosensitization induced by gemcitabine.Semantic proximity Read ↗

Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro.Semantic proximity Read ↗

Cell cycle effects of gemcitabineSemantic proximity Read ↗

Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breast carcinoma cell lines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.